Knowles stock reacts to new medtech manufacturing agreement

Knowles (KN) is back on investors’ radar after Elucent Medical announced an agreement for Knowles to produce a smart surgical guidance device for Elucent’s EnVisio In-Body Spatial Intelligence System.

The collaboration highlights Knowles’ precision manufacturing capabilities in medtech, including micro molding and other specialized processes. It also connects the stock’s recent move with fresh interest in its role as a manufacturing partner for regulated medical devices.

Against this backdrop, Knowles’ recent agreement with Elucent arrives after a strong run, with a year to date share price return of 77.77% and a 1 year total shareholder return of 85.72%. The 3 year total shareholder return of 139.53% points to longer term momentum that investors are now reassessing in light of new medtech contracts.

If this medtech story has your attention, it can be helpful to widen the lens and look at other specialist manufacturers and enablers of next generation infrastructure such as 36 power grid technology and infrastructure stocks

Knowles now sits on a strong multi year share price run and a fresh medtech contract that lifts expectations. How much of this move reflects durable earning power versus investors paying up for the story?

Most Popular Narrative: 10% Overvalued

The most followed narrative puts Knowles’ fair value at $39.00, almost exactly in line with the last close of $39.02, which tightens the focus on its underlying earnings story rather than any big discount.

Penetration of AI-enabled and IoT devices remains early stage, and Knowles' leadership in MEMS microphones and sensor components positions the company to capitalize on an explosive increase in device adoption, setting up structural, long-duration tailwinds in both recurring revenue and gross margin expansion.

Curious what supports that price tag for Knowles. The narrative leans on steady revenue expansion, higher profit margins and a richer earnings multiple. Want to see how those pieces fit together into one valuation story.

Result: Fair Value of $39.00 (OVERVALUED)

However, that bullish Knowles story runs into real risks if customer concentration bites or if rivals and vertical integration pressure margins and medtech demand.

Next Steps

If the mix of optimism and caution around Knowles feels finely balanced, now is a good time to examine the underlying data yourself and decide how it stacks up for your portfolio. To see what investors are focusing on, take a closer look at the 2 key rewards.

Looking for more investment ideas beyond Knowles?

If Knowles has sharpened your focus, do not stop here. Use the Simply Wall St Screener to uncover fresh opportunities that could suit your style and goals.

• Target potential mispricing by checking companies that pass the 49 high quality undervalued stocks and see which stocks the market might be overlooking.
• Strengthen your watchlist by scanning for companies in the solid balance sheet and fundamentals stocks screener (49 results) that pair financial resilience with fundamentals you can scrutinize in detail.
• Review the screener containing 20 high quality undiscovered gems to identify quality stocks before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.